A promising new combination therapy is offering new hope for patients with hard-to-treat cancers.

This is thanks to scientists at the Fralin Biomedical Research Institute in Virginia who have identified a potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival.

The study could help guide the development of new therapies for some treatment-resistant lung, brain and pancreatic cancers, according to the researchers.

"Using genetic screening, we found a new drug combination that seemingly works," said paper author and cancer biologist professor Kathleen Mulvaney in a statement.

Lung cancer is by far the most fatal type of cancer in the US, accounting for about one in five of all cancer deaths. Meanwhile, the five-year sur

See Full Page